Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$2.86
+3.2%
$2.52
$1.78
$8.56
$60.01M0.77110,500 shs132,946 shs
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$0.20
$0.17
$2.96
$13M-25.98N/AN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
$1.19
-0.8%
$1.32
$0.85
$4.29
$55.49M0.95344,455 shs339,454 shs
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$4.70
+1.5%
$5.22
$2.75
$11.00
$59.41M1.88382,440 shs563,583 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
0.00%+24.89%+0.70%+34.91%-55.66%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00%0.00%0.00%0.00%-56.53%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
0.00%+7.21%-0.83%-16.20%-60.60%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
0.00%+14.91%+1.08%-21.13%+48.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
3.9063 of 5 stars
3.43.00.04.82.40.80.0
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/AN/AN/AN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2.1092 of 5 stars
3.73.00.00.02.60.00.0
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
2.6328 of 5 stars
3.72.00.00.02.51.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
2.75
Moderate Buy$19.75590.56% Upside
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00
N/AN/AN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
3.33
Buy$9.00656.30% Upside
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
3.33
Buy$60.001,176.60% Upside

Current Analyst Ratings Breakdown

Latest CHHE, UNCY, PDSB, and ADVM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00
7/1/2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
6/26/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$16.00 ➝ $12.00
6/11/2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
5/27/2025
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$90.00
(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$1M60.00N/AN/A($0.96) per share-2.98
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$110K0.00N/A47.17N/ANaN
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/A$0.34 per shareN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/AN/AN/AN/A$0.72 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$130.93M-$7.85N/AN/AN/AN/A-297.29%-101.40%11/3/2025 (Estimated)
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
-$410K-$0.020.00N/AN/AN/AN/AN/AN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$37.61M-$0.92N/AN/AN/AN/A-184.56%-79.00%N/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$36.73M-$4.12N/AN/AN/AN/A-246.71%-116.96%N/A

Latest CHHE, UNCY, PDSB, and ADVM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$0.70-$0.52+$0.18-$0.52N/AN/A
8/13/2025Q2 2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$0.24-$0.21+$0.03-$0.21N/AN/A
8/12/2025Q2 2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$2.24-$2.34-$0.10-$2.34N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/AN/AN/AN/AN/A
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/AN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/A
1.54
3.57
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
0.81
2.92
2.33
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/A
1.64
1.64

Institutional Ownership

CompanyInstitutional Ownership
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
48.17%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
26.84%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
40.42%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
19020.98 million19.73 millionOptionable
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
4064.95 million44.62 millionNot Optionable
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2046.63 million42.34 millionOptionable
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
912.64 million11.29 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adverum Biotechnologies stock logo

Adverum Biotechnologies NASDAQ:ADVM

$2.86 +0.09 (+3.25%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$2.77 -0.09 (-3.29%)
As of 08/15/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

China Health Industries stock logo

China Health Industries OTCMKTS:CHHE

China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. The company operates through three segments: Humankind, HLJ Huimeijia, and Others. The company offers hemp derivative products, such as hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, hemp frozen age nourishing creams, hemp seed beers, and hemp seeds. It also provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin E for freckle removal and skin moisture supplements under the QunLe brand; and propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root under the Kindlink brand. In addition, the company offers health products for acne removal, relieving eyestrain, enhancing bone density, enhancing memory, enhancing nutritional anemia and chloasma, relaxing bowels and promoting the discharge of lead, enhancing immunity and relieving physical fatigue, and dispelling chloasma, as well as iron and multivitamin, and mineral supplements. Further, it manufactures and sells various types of medical drugs, such as enema glycerini, umguentumacidi borici camphoratum, ge hong beriberi water, pelvic inflammation suppository, injury and paralysis tincture, indometacin and furazolidone suppositories, injury and rheumatism relieving paste, refining goupi cream, muskiness pain relieving paste, muskiness bone strengthener paste, matrine suppositories, ethacriding lactate solution, iodine tincture, mercurochrome solution, hydrogen peroxide solution, halcinonide cream, compound fluocinonide tincture, and policresulen vaginal suppository. The company primarily sells its products through sales personnel and sales agents. China Health Industries Holdings, Inc. was founded in 1996 and is based in Harbin City, the People's Republic of China.

PDS Biotechnology stock logo

PDS Biotechnology NASDAQ:PDSB

$1.19 -0.01 (-0.83%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$1.22 +0.03 (+2.52%)
As of 08/15/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

Unicycive Therapeutics stock logo

Unicycive Therapeutics NASDAQ:UNCY

$4.70 +0.07 (+1.51%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$4.72 +0.02 (+0.43%)
As of 08/15/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.